PILOT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ABATACEPT IN ADULTS AND CHILDREN 6 YEARS AND OLDER WITH EXCESSIVE LOSS OF PROTEIN IN THE URINE DUE TO EITHER FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) OR MINIMAL CHANGE DISEASE (MCD):